Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
WARREN, N.J., Sept. 07, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
| Rodman & Renshaw 19th Annual Global Investment Conference | |
| Date: | Tuesday, September 12 |
| Time: | 9:35 am Eastern Time |
| Location: | The Lotte New York Palace Hotel, Kennedy I Ballroom |
| Webcast: | http://wsw.com/webcast/rrshq27/blph |
| Ladenburg Thalmann 3rd Annual Healthcare Conference | |
| Date: | Tuesday, September 26 |
| Time: | 1:30 pm Eastern Time |
| Location: | Sofitel Hotel, New York City, Orleans Ballroom |
| Webcast: | http://wsw.com/webcast/ladenburg3/blph |
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact Bellerophon Therapeutics: Fabian Tenenbaum, Chief Executive Officer (908) 574-4819 LifeSci Advisors Bob Yedid, Managing Director (646) 597-6989 [email protected]
